SERPINA1 and alpha 1-antitrypsin deficiency: They have developed the WVE-006 that uses targeted A→I RNA editing to repair the single-nucleotide Z mutation in SERPINA1 mRNA, enabling AATD (Pi*ZZ) patients to produce functional wild-type M-AAT protein rather than the misfolded, liver-toxic Z-AAT variant.